- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT03477994
Efficacy of Dexmedetomidine Versus Clonidine to Control Delirium in Patients Undergoing CABG
Efficacy of Dexmedetomidine Versus Clonidine to Control Delirium in Patients Undergoing Coronary Artery Bypass Grafting
This prospective, randomised, double blinded, controlled clinical trial will be conducted in 147 patients between 60 yr and 70 yr , ASA physical status II and III, undergoing CABG. Patients will be randomly allocated to either dexmedetomidine or clonidine (control) groups .Upon arrival to ICU, in the dexmedetomidine group, patients will receive an infusion of 0.5-0.7 μg/kg/h then 1.4 μg/kg/h if Richmond assessment sedation score from +1 to +4
Taking into consideration if the heart rate less than 60 per minute or persistent hypotension reduce infusion rate by 0.2 μg/kg/h.
Once the patient will be extubated, wean the infusion by 0.1μg/kg/h till reaching 0.2μg/kg/h. Slow the weaning rate if evidence of withdrawal reactions as agitation or hypertension occur. In clonidine group, the patients will receive 0.5μg/kg then 0.1-0.2 μg/kg/h.Primary end point of the study is the incidence of delirium.The secondary endpoints will be the the duration of extubation, the length of ICU stay, need for inotropic support or vasopressors, hospital stay , mean arterial blood pressure and heart rate , hospital mortality rate , all additional sedatives including overall doses of morphine and haloperidol the incidence of adverse events as bradycardia
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
After Ethics committee approval, and a written informed consent will be taken from every patient, . Patients with a history of mental illness, severe dementia, delirium or undergoing emergency procedures will be excluded.
Anesthesia management will be standardized to minimize any effect of anesthetic type on neurological outcomes. Premedication with midazolam will be limited to a maximum of 0.05 mg/kg.
Anesthesia will be induced with 12 μg/kg fentanyl, 5-7mg/kg thiopental sodium, and 0.15 mg/kg pancuronium and maintained with 1% to 2.0% isoflurane. The heart rate and blood pressure will be maintained within 20% of the baseline values. Anticoagulation will be achieved with heparin to maintain an activated clotting time above 480 s.The CPB circuit will be primed with 1.8 l lactated Ringer's solution and 50 ml of 20% mannitol. Management of CPB will include systemic temperature drift to 32 C, targeted mean perfusion pressure between 60 and 80 mmHg, and pump flow rates of 2.2 l/min/m2 . Myocardial protection will be achieved with antegrade cold blood cardioplegia. A 32-μ m filter (Avecor Affinity, USA)will be used in the arterial perfusion line. Before separation from CPB, patients will be rewarmed to 36 to 37C. After separation from CPB, heparin will be neutralized with protamine sulfate, 1 mg/100 U heparin, to reach an activated clotting time within 10% of baseline.All patients will be transferred to ICU after surgery. Patients will be randomly allocated to either dexmedetomidine or clonidine (control) groups according to a computer-generated randomization code, with allocation ratio 1:1 .Opaque sealed envelopes will be done according to the randomization schedule and opened by a physician not involved in the study . Upon arrival to ICU, in the dexmedetomidine group, patients will receive an infusion of 0.5-0.7 μg/kg/h then 1.4 μg/kg/h if Richmond assessment sedation score from +1 to +4
+4 Combative ,+3 Very agitated ,+2 Agitated,+1 Restless, 0 Alert and calm, -1 Drowsy , -2 Light sedation, -3 Moderate sedation, -4 Deep sedation, -5 Unarrousable A four millilitres vial of dexmedetomidine ( 100 micrograms per ml)will be drawn up and diluted in 46 ml of normal saline.The infusion of dexmedetomidine will be continued for a maximum period of 24 h. Taking into consideration if the heart rate less than 60 per minute or persistent hypotension reduce infusion rate by 0.2 μg/kg/h.Dexmedetomidine infusion will not be discontinued before extubation. Once the patient will be extubated, wean the infusion by 0.1μg/kg/h till reaching 0.2μg/kg/h. Slow the weaning rate if evidence of withdrawal reactions as agitation or hypertension occur. In clonidine group, the patients will receive 0.5μg/kg then 0.1-0.2 μg/kg/h.
Five ampoules of clonidine(750 μg) was drawn up and diluted in 45ml of normal saline.
Opioids were titrated to reach pain score 3 out of 10. Pain will be assessed using a standard 10-cm visual analog scale (0, no pain; 10, worst and unbearable pain). Patients received 2 mg morphine as rescue analgesic.
Primary end point of the study is the incidence of delirium, which is defined as a disturbed level of consciousness that develops over a period of hours or days and fluctuates over time.
Delirium will be assessed preoperatively (baseline)and postoperatively, in ICU every 2 hours using the confusion assessment method (CAM) for ICU.(7) When patients are discharged from ICU to the ward, delirium will be assessed using CAM every 8 hours for the next 5 days. The CAM-ICU is used for both ventilated and extubated patients. It included a fourstep algorithm : (1) an acute onset of changes or fluctuations in the course of mental status, (2)inattention, (3) disorganized thinking, and (4) an altered level of consciousness. Patients are delirious if both (1) and (2) were found inanition to either feature (3)or (4). Patients are stated either CAM positive (delirium present) or CAM negative (delirium absent). Incidence of delirium was confirmed by the psychiatry consultant. The onset and duration of delirium will be also recorded. The CAM-ICU and CAM testers were involved in the study . IV haloperidol(2.5-5 mg PRN), will be used as a first-line treatment in delirious patients, a regular dose 1 mg ads until symptoms resolve.
The secondary endpoints will be the the duration of extubation, the length of ICU stay, need for inotropic support or vasopressors, hospital stay , mean arterial blood pressure and heart rate , hospital mortality rate , all additional sedatives including overall doses of morphine and haloperidol, finally the incidence of adverse events as bradycardia, heart block , the need for pacemaker , nausea and vomiting will be recorded as well.
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiesteder
-
-
-
Cairo, Egypten, 11566
- Ain Shams University
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
60-70 yrs age ASA II, III Scheduled for CABG -
Exclusion Criteria:
History of mental illness Delirium or dementia patient refusal to participate Emergency procedures Any contraindications to study drugs
-
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Forebyggelse
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Dobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Aktiv komparator: dexmedetomidine group
Upon arrival to ICU, in the dexmedetomidine group, patients will receive an infusion of 0.5-0.7 μg/kg/h then 1.4 μg/kg/h if Richmond assessment sedation score from +1 to +4 +4 Combative ,+3 Very agitated ,+2 Agitated,+1 Restless, 0 Alert and calm, -1 Drowsy , -2 Light sedation, -3 Moderate sedation, -4 Deep sedation, -5 Unarrousable Taking into consideration if the heart rate less than 60 per minute or persistent hypotension reduce infusion rate by 0.2 μg/kg/h. Once the patient will be extubated, wean the infusion by 0.1μg/kg/h till reaching 0.2μg/kg/h. Slow the weaning rate if evidence of withdrawal reactions as agitation or hypertension occur. |
an infusion of 0.5-0.7 μg/kg/h then 1.4 μg/kg/h if Richmond assessment sedation score from +1 to +4 ,if the heart rate less than 60 per minute or persistent hypotension reduce infusion rate by 0.2 μg/kg/h.
Andre navne:
|
|
Sham-komparator: clonidine group
In clonidine group, the patients will receive 0.5μg/kg then 0.1-0.2
μg/kg/h if Richmond assessment sedation score from +1 to +4 Five ampoules of clonidine(750 μg) will be drawn up and diluted in 45ml of normal saline.
|
an infusion of 0.5μg/kg then 0.1-0.2
μg/kg/h if Richmond assessment sedation score from +1 to +4.
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
the incidence of delirium
Tidsramme: every 4 hours in first day in ICU then every 8h for the next day, after discharge from ICU to the ward it will be checked every 8h for 5 days
|
disturbed level of consciousness that develops over a period of hours or days and fluctuates over time.
|
every 4 hours in first day in ICU then every 8h for the next day, after discharge from ICU to the ward it will be checked every 8h for 5 days
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
length of ICU stay
Tidsramme: 2 days
|
time to stay in ICU discharge to the ward
|
2 days
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Studiestol: Ayman Shoeb, professor, Ain Shams University
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Psykiske lidelser
- Patologiske processer
- Sygdomme i nervesystemet
- Postoperative komplikationer
- Neurologiske manifestationer
- Forvirring
- Neuroadfærdsmæssige manifestationer
- Neurokognitive lidelser
- Delirium
- Emergence Delirium
- Lægemidlers fysiologiske virkninger
- Adrenerge midler
- Neurotransmittermidler
- Molekylære mekanismer for farmakologisk virkning
- Antihypertensive midler
- Depressive midler til centralnervesystemet
- Autonome agenter
- Agenter fra det perifere nervesystem
- Analgetika
- Sensoriske systemagenter
- Analgetika, ikke-narkotisk
- Adrenerge alfa-2-receptoragonister
- Adrenerge alfa-agonister
- Adrenerge agonister
- Hypnotika og beroligende midler
- Sympatolytika
- Dexmedetomidin
- Clonidin
Andre undersøgelses-id-numre
- FMASU R 16
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
IPD-delingstidsramme
IPD-delingsadgangskriterier
IPD-deling Understøttende informationstype
- STUDY_PROTOCOL
- SAP
- ICF
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Delirium på Emergence
-
Yonsei UniversityAfsluttetPostoperativt delirium efter on-pump hjertekirurgiKorea, Republikken
-
West China HospitalRekrutteringOn-pumpe ventilkirurgi eller CABGKina
-
Yonsei UniversityAfsluttetPerifer cirkulation under on-pump hjertekirurgiKorea, Republikken
-
Taipei City HospitalAfsluttetPRU (blodpladereaktivitetsenhed) | APT (Antiplatelet Therapy) | HOTPR (High on Treat Platelet Reactivity)Taiwan
-
OHSU Knight Cancer InstituteOregon Health and Science UniversityAktiv, ikke rekrutterendeAdenocarcinom i bugspytkirtlen | Fase III Pancreas Cancer American Joint Committee on Cancer v8 | Stadium 0 Bugspytkirtelkræft American Joint Committee on Cancer v8 | Stadium I Bugspytkirtelkræft American Joint Committee on Cancer v8 | Stadie IV Bugspytkirtelkræft American Joint Committee on...Forenede Stater
-
October 6 UniversityIkke rekrutterer endnuPræcision af aftryksteknikker i All-on-x tilfælde | Nøjagtighed af aftryk til fuldbueimplantatproteseEgypten
-
Ahmet YuksekAfsluttetCABG | Anæstesi | Bypass komplikation | Hjertekirurgisk prognose | On-pumpe ventilkirurgi eller CABG | HjerteanæstesiTyrkiet (Türkiye)
-
University of UtahNational Cancer Institute (NCI)AfsluttetTræthed | Stillesiddende livsstil | Metastatisk prostatakarcinom | Stage IV Prostata Cancer AJCC (American Joint Committee on Cancer) v8 | Stage IVA Prostata Cancer AJCC (American Joint Committee on Cancer) v8 | Stage IVB Prostata Cancer AJCC (American Joint Committee on Cancer) v8Forenede Stater
-
Alexandria UniversityAfsluttetClozapinforgiftning | Hypoaktivt delirium | Tricyklisk antidepressiv forgiftning | Antikolinerg delirium | Antipsykotisk Toksicitet | CNS-depression | Procyclidininduceret deliriumEgypten
-
University Hospital, BordeauxRekrutteringOn-pump hjertekirurgi | Høj risiko for blødning | AutotransfusionFrankrig
Kliniske forsøg med Dexmedetomidine
-
Bahria International HospitalAfsluttet
-
Cairo UniversityRekrutteringBupivacain | Intratekal dexmedetomidin | Knæ-ortopædisk kirurgiEgypten
-
Peking University First HospitalRekrutteringDelirium | Dexmedetomidin | Postoperativ pleje | Intensivafdeling | Ældre patienter | EsketaminKina
-
Indonesia UniversityAfsluttetKnækirurgi | Bækkenkirurgi | Spinal anæstesiIndonesien
-
McGill University Health Centre/Research Institute...RekrutteringAnalgesi | Smerter, Akut | Nerveblok | Øvre ekstremitetskirurgiCanada
-
Benha UniversityRekrutteringDelirium - PostoperativtEgypten
-
Al-Azhar UniversityBenha UniversityIkke rekrutterer endnuPost-spinal rystenEgypten
-
Sichuan Academy of Medical SciencesIkke rekrutterer endnuSepsis | Septisk chok
-
Younes Ahmed YounesIkke rekrutterer endnu
-
Cairo UniversityUkendtSpinal anæstesi VarighedEgypten